Spectrum of HIV lymphoma 2009. Review uri icon

Overview

abstract

  • PURPOSE OF REVIEW: HIV-infected individuals remain at an increased risk for developing malignancies despite the use of combined antiretroviral therapy. Lymphomas comprise a large proportion of the malignancies that affect the HIV-infected population in developed countries. This review summarizes the recent progress made in HIV lymphoma research published in 2009 through January 2010. RECENT FINDINGS: The majority of investigation in this field has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising. Rituximab likely improves complete response and possibly overall survival, but may be associated with increased infections in a subset of patients with very low CD4 cell counts. Risk factors associated with the development of lymphoma include low CD4 cell count and likely cumulative HIV viremia. Biologic insights have been realized regarding pathogenesis. SUMMARY: Overall, the outcome for HIV lymphoma continues to improve as insights into the pathophysiology and treatment advance.

publication date

  • July 1, 2010

Research

keywords

  • Antiretroviral Therapy, Highly Active
  • HIV Infections
  • Lymphoma, AIDS-Related
  • Stem Cell Transplantation

Identity

Scopus Document Identifier

  • 77955681258

Digital Object Identifier (DOI)

  • 10.1097/MOH.0b013e328338f6b6

PubMed ID

  • 20442655

Additional Document Info

volume

  • 17

issue

  • 4